Mobile

This is a clinical research study involving an experimental drug named GS-6624 for the treatment of metastatic colorectal adenocarcinoma, a sub-type of cancer of the colon and/or rectum. The pur...

Update Il y a 4 ans
Reference: EUCTR2011-003754-61

This is a clinical research study involving an experimental drug named GS-6624 for the treatment of metastatic colorectal adenocarcinoma, a sub-type of cancer of the colon and/or rectum. The purpose of this study is to test the effectiveness and safety of GS-6624 at different dose levels when it is given with FOLFIRI. We want to find out what effects, good and/or bad, GS-6624 has on you and your metastatic colorectal adenocarcinoma when it is given with FOLFIRI

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare the additive efficacy of GS-6624 vs. placebo in combination with FOLFIRI as measured by improvement in progression free survival (PFS) in subjects with metastatic KRAS mutant colorectal adenocarcinoma who have progressed following a first line oxaliplatin- and fluoropyrimidine-containing regimen.

Inclusion criteria

  • Metastatic KRAS Mutant Colorectal Adenocarcinoma

Links